ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Industry, Academia Join In California

by Michael McCoy
February 17, 2014 | APPEARED IN VOLUME 92, ISSUE 7

MedImmune, the biologics arm of AstraZeneca, has entered a three-year research collaboration with the Clinical & Translational Science Institute at the University of California, San Francisco. The pact will focus on the institute’s Catalyst Awards program, which solicits applications from university scientists who want to move their research beyond the bench. The partners say they will work together to move the most promising research projects forward. MedImmune says the collaboration should benefit its R&D as well as AstraZeneca’s small-molecule drug discovery efforts.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment